Instrument Inactif

Communiqués Allergan, Inc.

Actions

US0184901025

Produits pharmaceutiques

Cours en clôture NYSE
- ^USD	-

09/05/17	Les valeurs à suivre mardi 9 mai 2016 à Wall Street -
09/05/17	ALLERGAN : dépasse les attentes

Communiqués

07/06/17	Allergan : to Present New Data on Chronic Migraine at the American Headache Society Meeting in Boston	PU
31/05/17	Allergan : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 2017 in New Orleans	PU
24/05/17	Allergan : Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1%	PU
16/05/17	Allergan : Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications	PU
04/05/17	Allergan : to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego	PU
13/04/17	Allergan : and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)	PU
11/04/17	Allergan : Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art	PU
07/04/17	Allergan : Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk	PU
22/03/17	Allergan : Announces Availability of RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle	PU
20/03/17	Allergan : JUVÉDERM VOLLURE™ XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21	PU
14/03/17	Allergan : New Survey Reveals Impact Of Double Chin On Self-Perception And Behavior	PU
27/02/17	Allergan : New Eyepowerment™ Campaign Urges The Up To 33 Million Americans Suffering from Symptoms of Chronic Dry Eye to Take Action	PU
07/02/17	Allergan : Launches See America(SM), a Bold Initiative Furthering the Fight Against Preventable Blindness	PU
27/01/17	Allergan : Launches Juvéderm® Volite - an Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months	PU
26/01/17	Allergan : U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation	PU
19/01/17	Allergan : Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults	PU
17/01/17	Allergan : and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids	PU
16/11/16	Allergan : Announces Partnership with Amy Dixon, Elite Paratriathlete, to Improve Patient-Physician Conversations About Irritable Bowel Syndrome with Diarrhea (IBS-D)	PU
10/11/16	Allergan : Announces Launch of TAYTULLA™ (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules) 1 mg/20 mcg, the First and Only Oral Contraceptive Softgel Capsule	PU
28/10/16	Allergan : Introduces RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a New Delivery System for the One and Only FDA Approved Treatment to Help Patients Produce More of Their Own Tears	PU
26/10/16	Allergan : Announces Changes to Board Leadership	PU
18/10/16	Allergan : JUVÉDERM VOLBELLA® XC Now Available To Doctors And Patients In The U.S.	PU
16/10/16	Allergan : Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL	PU
14/10/16	Allergan : Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016	PU
20/09/16	Allergan : Acquires Akarna Therapeutics Adding to its Strong Development Program and Commitment to Innovation in NASH	PU